Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics director Arthur Tzianabos received a grant of options for 17,786 shares of common stock. The Director Stock Option has an exercise price of $29.46 per share and expires on June 2, 2036. It will vest in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Stoke Therapeutics director Julie Smith received a new stock option grant. On June 3, 2026, she was awarded options covering 17,786 shares of common stock at an exercise price of $29.46 per share. The options vest in full on June 3, 2027 or the date of the next annual stockholder meeting, subject to her continued service, and expire on June 2, 2036.
Stoke Therapeutics director Arthur A. Levin received a grant of stock options covering 17,786 shares of common stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036. According to the grant terms, the award vests in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, contingent on Levin’s continued service.
Stoke Therapeutics director Adrian R. Krainer received a grant of 17,786 stock options to buy common shares at $29.46 each. These Director Stock Options were awarded for compensation, not purchased on the open market, and are held as a direct beneficial interest.
The options vest in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, as long as Krainer continues serving the company through that date. Following this grant, he holds 17,786 options covering the same number of common shares, which may be exercised before their expiration on June 2, 2036.
Stoke Therapeutics, Inc. reported that director Edward M. Kaye, MD received a grant of options to acquire 17,786 shares of Common Stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036.
According to the terms, the option vests in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, subject to his continued service with the company through that vesting date. This is a compensation-related award rather than an open-market stock purchase.
Stoke Therapeutics director Seth Loring Harrison received a grant of 17,786 stock options. These Director Stock Options give him the right to buy 17,786 shares of common stock at an exercise price of $29.46 per share and are held directly.
The options vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, as long as he continues serving the company through that vesting date. The options expire on June 2, 2036, and this grant represents his full reported option position in this filing. This is a compensation award, not an open‑market stock purchase or sale.
Stoke Therapeutics director Jennifer Burstein received a grant of stock options covering 17,786 shares of common stock. These options have an exercise price of $29.46 per share and expire on June 2, 2036. The filing shows she holds 17,786 derivative securities following this grant. According to the vesting terms, the option will vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, provided she continues serving the company through that vesting date.
Stoke Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Stockholders elected directors G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith, each receiving tens of millions of shares voted in favor versus relatively small withheld votes, plus broker non-votes.
Stockholders also approved one proposal with 55,121,163 shares for, 2,036 against, and 51,714 abstaining, and another with 36,436,275 shares for, 13,565,293 against, 29,415 abstaining, and 5,143,930 broker non-votes. The filing confirms that these meeting outcomes are now formally recorded.
Stoke Therapeutics, Inc. Chief Medical Officer Barry Ticho reported an open-market sale of 1,795 shares of common stock at $30.58 per share. After the transaction, he directly holds 34,826 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance.
Stoke Therapeutics reports a Schedule 13G/A showing beneficial ownership of 4,763,673 shares (8.1% of the class). The filing states this percentage is calculated using 59,150,790 shares outstanding as of February 28, 2026. The holdings are reported by Lynx1 Capital Management LP and Weston Nichols and consist of 4,121,244 shares previously reported for the quarter ended March 31, 2026 plus an additional 642,429 shares.